Telix Pharmaceuticals to Acquire ITM Isotope Technologies in $1.65 B Deal
Telix Pharmaceuticals will purchase ITM Isotope Technologies Munich SE in a transaction valued at at least $1.65 billion.
The deal gives Telix full ownership of ITM, with a possible extra $700 million payment if ITM’s lead drug meets regulatory and sales milestones. The combined company joins a market currently led by Novartis, which launched radiopharmaceutical cancer treatments in 2018 and 2022.
Why it matters
The merger could reshape competition in the fast-growing radiopharmaceutical cancer-treatment market.
In this story
radiopharmaceuticalsmerger$1.65 billion$700 million earnoutcancer treatmentradioactive isotopesmarket dominance
